[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-implantation-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-implantation-failure":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,84,123,146,172,199,225],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100643215","zishen-yutai-pill-for-patients-with-recurrent-implantation-failure-100643215",false,"NCT07641088","Zishen Yutai Pill for Patients With Recurrent Implantation Failure","Zishen Yutai Pill for Patients With Recurrent Implantation Failure: a Randomized, Double-blind, Parallel-group, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Meet the diagnostic criteria for recurrent implantation failure;\n2. Aged between 20-40 years old (inclusive) when oocytes were retrieved, and \\\u003C43 at enrollment;\n3. Have at least 1 good-quality embryo for transfer;\n4. Intend to undergo frozen-thawed embryo transfer;\n5. Voluntary participation and signed informed consent.\n\nExclusion Criteria:\n\n1. Concomitant unresolved intrauterine lesions (e.g., intrauterine adhesions grade III-IV, endometrial polyps ≥1 cm, acute endometritis), endometriosis (ASRM stage ≥III), or adenomyosis (uterine volume ≥8 weeks of gestation) that affect embryo implantation;\n2. Intend to undergo FET after preimplantation genetic testing (PGT), including aneuploidy screening (PGT-A), monogenic disease testing (PGT-M), chromosomal structural rearrangement testing (PGT-SR);\n3. Thin endometrium (\\\u003C7 mm) before enrollment;\n4. Concomitant severe genital malformations or genital neoplasms;\n5. Contraindications to estrogen and progestogen (e.g., history of breast cancer);\n6. Presence of medical contraindications to assisted reproductive technology, including that either partner has a severe psychiatric disorder, acute genitourinary tract infection, sexually transmitted disease, serious deleterious habit (e.g., drug abuse), or teratogenic exposure to radiation, toxic agent or medication that still under effect; or genetic diseases specified in the Law of the People's Republic of China on Maternal and Infant Health Care for which childbearing and PGT are contraindicated; or severe somatic diseases incompatible with pregnancy; or chromosomal abnormalities;\n7. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>1.5 × the upper limit of normal (ULN), or serum creatinine (Scr) \\> ULN;\n8. Presence of poorly controlled severe systemic diseases, including cardiovascular, digestive, endocrine, and autoimmune diseases (e.g., antiphospholipid syndrome, Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis);\n9. Use of traditional Chinese medicines with similar functions and indications to ZYP within 1 month before screening that may affect treatment efficacy. Chinese patent medicines such as Tiaojing Cuyun Pills, Kuntai Capsules, Peikun Pills, Qilin Pills, Jinfeng Pills, Gushen Antai Pills, and Chinese herbal decoctions containing Cuscutae Semen, Dipsaci Radix, Taxilli Herba, and Asini Corii Colla with kidney-tonifying and spleen-strengthening effects;\n10. Allergy to any component of the study drugs;\n11. Participated in another interventional trials within 1 month prior to enrollment;\n12. Deemed unsuitable for this study by the investigator.","FEMALE","20 Years","43 Years",{"count":20,"type":21},878,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate the efficacy of Zishen Yutai Pill (ZYP) on pregnancy outcomes following embryo transfer and its safety in patients with recurrent implantation failure. The main question it aims to answer is whether ZYP can improve live birth rate in participant's frozen embryo transfer (FET) cycles.\n\nResearchers will compare ZYP to a placebo (a look-alike substance with similar characteristics to ZYP) to see if it works to improve pregnancy outcomes.\n\nParticipants will:\n\n1. Start to receive ZYP or placebo (5g per time, 3 times daily) within the first 5 days of their initial menstrual cycle, and will undergo FET in the following cycle. The medication will be taken without interruption till the day of pregnancy test (2 weeks after embryo transfer). Patients with positive results in β-HCG test will continue to take the drug until clinical pregnancy confirmation by ultrasound three weeks later. For those with a negative β-HCG result, the intervention will be stopped.\n2. Baseline visit will be conducted on days 2-4 of the participant's first menstrual cycle. Subsequent clinic visits will follow the standard protocol for FET cycle, as outlined below:\n\nVisit 1 (days 2-4 of the second menstrual cycle); Visit 2 (day of ovulation or day of endometrial transformation); Visit 3 (day of embryo transfer); Visit 4 (2 weeks after embryo transfer); Visit 5 (5 weeks after embryo transfer). Follow-up is scheduled at 10 weeks after embryo transfer (Visit 6) and after delivery (Visit 7), and these can be conducted remotely.",[27],"Recurrent Implantation Failure",[29,30,31,32,33],"traditional Chinese medicine","Zishen Yutai pill","recurrent implantation failure","frozen-thawed embryo transfer","randomized controlled trial","NOT_YET_RECRUITING","2026-06-10",{"date":37,"type":38},"2026-06-11","ACTUAL",{"date":40,"type":21},"2026-07-01",{"date":42,"type":21},"2029-12-31",{"name":44,"class":45},"Peking University Third Hospital","OTHER",13,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":67,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":4},"100627987","experimental-study-on-the-use-of-intrauterine-infusion-of-autologous-platelet-rich-plasma-prgf-iui-in-patients-with-recurrent-implantation-failure-andor-refractory-thin-endometrium-100627987","NCT07455773","Experimental Study on the Use of Intrauterine Infusion of Autologous Platelet-rich Plasma (PRGF-IUI) in Patients With Recurrent Implantation Failure and\u002For Refractory Thin Endometrium","PMA_PREPAIRE STUDY: Experimental Study on the Use of Intrauterine Infusion of Autologous Platelet-rich Plasma (PRGF-IUI) in Patients With Recurrent Implantation Failure and\u002For Refractory Thin Endometrium.","PMA_PREPAIRE","Inclusion Criteria:\n\n* Female patients aged 18 to 45 years\n* Body mass index (BMI) between 18 and 30 kg\u002Fm\n* Undergoing assisted reproductive technology (ART) cycle with hormone replacement therapy\n* Endometrial thickness \\\u003C 7 mm after at least 10 days of hormone replacement therapy\n* History of at least one failed embryo transfer\n* Normal hematologic and biochemical laboratory results\n* Ability to understand and sign written informed consent\n\nExclusion Criteria:\n\n* Endometrial hyperplasia or uterine malignancy\n* Active pelvic inflammatory disease or untreated sexually transmitted infection\n* Coagulation disorders or platelet abnormalities\n* Thrombocytopenia (\\\u003C100,000\u002Fmm³)\n* Chronic anticoagulant therapy\n* Active systemic infection or immunodeficiency\n* Contraindications to intrauterine procedures","18 Years","45 Years",{"count":58,"type":21},80,[24],"Endometrial receptivity is a key determinant of success in assisted reproductive technology (ART). A significant proportion of patients experience repeated implantation failure despite euploid embryos and adequate laboratory conditions. Thin endometrium, often defined as ultrasound-measured thickness \\\u003C7 mm at embryo transfer, is frequently refractory to estrogen therapy and associated with low implantation and clinical pregnancy rates.\n\nPlatelet-Rich Plasma (PRP), obtained from autologous blood by double centrifugation, is rich in growth factors capable of stimulating cell proliferation, angiogenesis, and tissue regeneration, suggesting potential benefits for endometrial function. Preliminary studies indicate improved endometrial thickness and reproductive outcomes following intrauterine PRP infusion, but standardized protocols and systematic data are lacking.\n\nThe PMA\\_PREPAIRE study is a prospective, single-center, controlled, non-randomized interventional clinical trial conducted at the Reproductive Medicine Center of Cardinal Massaia Hospital, Asti. The study aims to evaluate the efficacy and safety of intrauterine infusion of autologous platelet-rich plasma (PRP), in association with hormone replacement therapy (HRT), in improving endometrial receptivity and reproductive outcomes in women with thin or refractory endometrium. The study includes a prospective control group treated with standard HRT alone.\n\nEligible women will be treated with standard clinical care, with PRP infusion offered to those with insufficient response to HRT. Inclusion criteria include age 18-45, BMI 18-30 kg\u002Fm², history of ≥1 failed embryo transfer, EMT \\\u003C5 mm after ≥10 days of HRT, and normal routine lab tests. Exclusion criteria include endometrial disease, recent gynecological infection, and systemic conditions such as thrombocytopenia or coagulopathies.\n\nProcedures include standard HRT from cycle days 1-2, serial ultrasound monitoring of endometrial thickness from days 6-8, intrauterine PRP infusion if EMT ≤7 mm (up to three infusions per cycle), embryo transfer once EMT ≥7 mm, and follow-up through pregnancy testing and confirmatory ultrasound.\n\nCollected data will be analyzed using descriptive statistics, paired and unpaired comparative analyses, and multivariate logistic regression models to evaluate predictors of treatment response and reproductive outcomes (significance level p \\\u003C 0.05).\n\nA sample size of 34 patients per group was estimated to detect a 1.5 mm difference in endometrial thickness (EMT) with 90% statistical power. Considering an anticipated dropout rate of 15%, a total of 40 patients per group will be enrolled.\n\nThe study includes:\n\nan intervention group consisting of 40 patients treated with HRT plus intrauterine PRP infusion; a prospective control group consisting of 40 patients with refractory thin endometrium treated with standard HRT alone, without PRP.",[27,62,63,64,65,66],"Endometrial Receptivity Disorders","Embryo Implantation","Platelet-Rich Plasma","Platelet-rich Plasma (PRP)","Infertility, Female",[68,69,70,71,72,73],"Endometrial receptivity","Recurrent implantation failure","Assisted reproductive technology","Platelet-rich plasma","Intrauterine infusion","Autologous biological therapy","2026-05-12",{"date":76,"type":38},"2026-05-14",{"date":78,"type":21},"2026-05-01",{"date":80,"type":21},"2027-12",{"name":82,"class":83},"Azienda Sanitaria Locale di Asti","OTHER_GOV",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":96,"conditions":97,"keywords":103,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100613355","study-of-endometrial-immune-and-microbiological-modifications-in-cases-of-recurrent-implantation-failure-andor-recurrent-pregnancy-loss-100613355","NCT07265505","Study of Endometrial Immune and Microbiological Modifications in Cases of Recurrent Implantation Failure and\u002For Recurrent Pregnancy Loss","Study of Immune and Microbiological Modifications of the Endometrium in Cases of Recurrent Implantation Failure and\u002For Recurrent Pregnancy Loss","IMERR","Inclusion Criteria:\n\n* Female aged ≥18 and \\\u003C36 years\n* Undergoing assisted reproductive technology (ART) in a fertility center\n* Covered by the French national health insurance system\n* Belonging to one of two groups:\n\n  * Study group: history of recurrent implantation failure (RIF) and\u002For recurrent pregnancy loss (RPL)\n  * Control group: no history of RIF or RPL\n\nExclusion Criteria:\n\n* Pregnant at inclusion\n* Refusal to provide written informed consent\n* Antibiotic use within one month prior to endometrial biopsy Positive serology for hepatitis B, hepatitis C or HIV\n* Uterine anatomical abnormalities (e.g., polyps, cavity-distorting fibroids, untreated hydrosalpinx)\n* Known chromosomal abnormality in either partner\n* Known autoimmune disease, thrombophilia, or antiphospholipid antibody syndrome\n* Persons under legal protection (e.g., guardianship, curatorship)","35 Years",{"count":94,"type":21},100,[24],"The IMERR study aims to improve understanding of certain causes of infertility related to recurrent implantation failure (RIF) and\u002For recurrent pregnancy loss (RPL), conditions that affect many women undergoing assisted reproductive technology (ART). Despite medical advances, some patients repeatedly fail to achieve pregnancy, or experience repeated miscarriages. These situations may be linked to subtle immune or microbial disturbances in the uterus. This study seeks to identify immune and microbiological profiles in the endometrium during the implantation window-a crucial period when the embryo attaches to the uterine wall. We will compare women who have experienced RIF and\u002For RPL with women who have had no such history. Blood and uterine samples will be analyzed to investigate whether certain immune or microbial features are associated with these reproductive failures. The ultimate goal is to uncover predictive factors that may explain why some women experience implantation failure or pregnancy loss, and to lay the foundation for future personalized treatments to improve reproductive outcomes.",[27,98,66,99,100,101,102],"Recurrent Pregnancy Loss","Endometrial Diseases","Endometritis","Endometriosis","Adenomyosis",[104,105,106,107,108,109,110,111,112,102,101],"Uterine Immune Profile","Endometrial Receptivity","Infertility","Recurrent Miscarriage","IVF Failure","Implantation Window","Reproductive Immunology","Endometrial Microbiome","Chronic Endometritis","2026-02-03",{"date":115,"type":38},"2026-02-05",{"date":117,"type":21},"2026-04",{"date":119,"type":21},"2031-04",{"name":121,"class":45},"Assistance Publique - Hôpitaux de Paris",1,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":4},"100620853","efficacy-of-a-non-invasive-endometrial-receptivity-prediction-model-based-on-peripheral-blood-mirna-signatures-during-the-peri-implantation-period-in-improving-ivf-outcomes-in-patients-with-unexplained-rif-100620853","NCT07363018","Efficacy of a Non-Invasive Endometrial Receptivity Prediction Model Based on Peripheral Blood miRNA Signatures During the Peri-Implantation Period in Improving IVF Outcomes in Patients With Unexplained RIF","Efficacy of a Non-Invasive Endometrial Receptivity Prediction Model Based on Peripheral Blood miRNA Signatures During the Peri-Implantation Period in Improving IVF Outcomes in Patients With Unexplained Recurrent Implantation Failure: A Prospective, Single-Blind, Two-Arm, Parallel Randomized Controlled Trial","RIF","Inclusion Criteria:\n\n1. Patients with unexplained recurrent implantation failure (RIF) meeting the diagnostic criteria for RIF: adult women under 40 years old who have failed to achieve clinical pregnancy after 3 embryo transfer cycles; or after transferring at least 3 high-quality embryos.\n\n   Definition of high-quality embryos: Day 3 embryos (with a cell count ≥7 and fragmentation rate \\\u003C10%) and blastocysts (≥3BB).\n2. Female BMI: 18.5-25 kg\u002Fm².\n3. Endometrial thickness ≥7 mm during the embryo transfer cycle.\n4. Women planning to undergo frozen-thawed embryo transfer (FET) of blastocysts following in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).\n5. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Known causes of embryo implantation failure, such as infections, reproductive tract malformations, uterine cavity factors, adenomyosis or endometriosis, autoimmune system diseases (diagnosed by immunology department), hydrosalpinx, etc.\n2. Couples with chromosomal abnormalities (excluding chromosomal polymorphisms) or familial genetic disorders in either or both partners.\n3. Women with a history of recurrent miscarriage.\n4. Women with contraindications to pregnancy or assisted reproductive technology.","39 Years",{"count":133,"type":21},546,[24],"The goal of this clinical trial aims to investigate whether a non-invasive implantation window prediction model, constructed based on characteristic changes in peripheral blood miRNAs during the peri-implantation period, can improve pregnancy outcomes in patients with unexplained recurrent implantation failure undergoing frozen embryo transfer. Researchers will compare the clinical pregnancy outcomes between individualized embryo transfer guided by implantation window results and conventional embryo transfer, to observe whether implantation window-guided individualized embryo transfer can improve the clinical efficacy for patients with recurrent implantation failure (RIF). Participants will complete implantation window testing as required by the study protocol, undergo randomization and blinding, and proceed with embryo transfer according to their assigned group.",[27],"2026-01-15",{"date":139,"type":38},"2026-01-23",{"date":141,"type":21},"2026-02",{"date":143,"type":21},"2027-09",{"name":145,"class":45},"Tang-Du Hospital",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":162,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":122},"100452287","association-between-plasma-level-of-mannose-binding-lectin-and-human-reproduction-100452287","NCT05169541","Association Between Plasma Level of Mannose Binding Lectin and Human Reproduction","Is Plasma Level of Mannose Binding Lectin Associated With Reproductive Failure?","Inclusion Criteria:\n\nfulfil one of the following:\n\n* 3 consecutive pregnancy losses after spontaneous conception\n* 3 consecutive pregnancy losses after assisted reproductive technology treatment (ART) including IVF, ICSI and FET\n* 3 failed embryo transfers characterized by no achieved pregnancy (after 3 cycles with minimum 1 embryo transfer of a good-quality embryo in each cycle.)\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>45 years\n* AMH \\\u003C4.0 pmol\u002Fl unless donor egg in previous cycles\n* Significant uterine malformation\n* Known endometrial pathologies including intrauterine endometriosis, adenomyosis, hyperplasia or polyps\n* Known chromosomal abnormalities\n* Pregnancy \\>9 weeks of gestation at the time collecting the blood sample","41 Years",{"count":155,"type":21},500,"OBSERVATIONAL","A low plasma level of mannose binding lectin (p-MBL) is associated with unexplained recurrent pregnancy loss (RPL), but it is not investigated if it is associated with unexplained reproductive failure in general, including recurrent implantation failure (RIF) after assisted reproductive technology (ART) (including IVF, ICSI and FET), recurrent pregnancy loss (RPL) after spontaneous conception, and RPL after ART.",[159,98,27,106,160,107,161],"Mannose-Binding Lectin Deficiency","Habitual Abortion","Recurrent Spontaneous Abortion","RECRUITING","2025-11-20",{"date":165,"type":38},"2025-11-24",{"date":167,"type":38},"2016-01-01",{"date":169,"type":21},"2026-11-30",{"name":171,"class":45},"Aalborg University Hospital",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":179,"sex":16,"minAge":55,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":185,"conditions":186,"keywords":189,"overallStatus":162,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":197,"locationsCount":122},"100465657","early-phase-1-bone-marrow-derived-stem-cells-mobilization-for-treatment-of-abnormal-endometrium-100465657","NCT05343572","Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium","Bone Marrow Derived Stem Cells Mobilization for Treatment of Asherman's Syndrome, Atrophic Endometrium, and Recurrent Implantation Failure","Inclusion Criteria:\n\n* Healthy, non pregnant females\n* ages ≥18 and ≤40 years old at time of enrollment\n* with either AS, AE, or RIF\n\n  1. For AS: surgical history of intrauterine trauma\u002Finfection, hypo\u002Famenorrhea, intra-uterine adhesions\n  2. for AE: US documentation of persistent, \\\u003C6mm endometrial thickness\n  3. for RIF: failure to achieve a clinical pregnancy after transfer of at least four good-quality embryos in a minimum of three fresh or frozen cycles in a woman under 40 years and currently being treated at Yale Fertility Clinic\n\nExclusion Criteria:\n\n* Presence of hydrosalpinx (diagnosed by radiographic or ultrasound imaging)\n* Endometriosis (diagnosed by previous surgery,)\n* Diminished ovarian reserve (AMH\\\u003C1ng\u002Fml or follicle stimulating hormone (FSH)\\>10)\n* History of genital tuberculosis or any ultrasound evidence of congenital uterine anomaly\n* Submucous or intracavitary fibroid, polyps\n* Currently pregnant\n* Personal history of thrombophilia or sickle cell disease\n* Inability to provide informed consent",true,"40 Years",{"count":182,"type":21},90,[184],"EARLY_PHASE1","This study will assess the use of autologous bone marrow stem cells mobilization using 1,1'-\\[1,4-phenylenebis-(methylene)\\]-bis-1,4,8,11-tetraazacyclotetradecane (PLERIXAFOR) as an effective medical therapy for the treatment of Asherman's Syndrome (AS), Atrophic Endometrium (AE) and Recurrent Implantation Failure (RIF).",[187,188,27],"Asherman Syndrome","Atrophic Endometrium",[190],"bone marrow derived stem cells","2025-11-07",{"date":193,"type":38},"2025-11-12",{"date":195,"type":38},"2023-11-01",{"date":80,"type":21},{"name":198,"class":45},"Hugh Taylor",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":180,"enrollmentInfo":206,"targetDuration":4,"studyType":22,"phases":208,"briefSummary":209,"conditions":210,"keywords":211,"overallStatus":162,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":122},"100574695","comparing-fet-guided-by-era-vs-standard-timing-in-patients-with-recurrent-implantation-failure-100574695","NCT06762626","Comparing FET Guided by ERA Vs Standard Timing in Patients with Recurrent Implantation Failure","A Randomized Controlled Trial Comparing Frozen Embryo Transfer Guided by Endometrial Receptivity Analysis Vs Standard Timing in Patients with Recurrent Implantation Failure","Inclusion Criteria:\n\n1. Women with recurrent implantation failure\n2. Women aged \\\u003C 40 years\n3. Body mass index of women between 18.5 (inclusive) and 30 (exclusive) kg\u002Fm²\n4. Women with at least one high quality frozen blastocyst (BB grade or above) and planning to undergo a single blastocyst transfer\n5. Women who will give written informed consent\n\nExclusion Criteria:\n\n1. Women with recurrent pregnancy loss (3 or more biochemical or spontaneous miscarriages)\n2. Either partner with known chromosomal abnormalities including balanced translocations\n3. Women undergoing preimplantation genetic testing\n4. Women with endometrial thickness \\\u003C 7 mm in the IVF cycle\n5. Women with a confirmed diagnosis of stage III-IV endometriosis or adenomyosis affecting uterine cavity morphology\n6. Women with a confirmed diagnosis of antiphospholipid syndrome\n7. Pathologies affecting the uterine cavity, including polyps, submucosal fibroids, intramural fibroids \\> 4 cm, or hydrosalpinx",{"count":207,"type":21},734,[24],"The pregnancy rate of in vitro fertilisation (IVF) remains around 35% per transfer. Women who are not pregnant following several embryo transfers are regarded as having recurrent implantation failure (RIF), with one of the causes being the asynchronization of the embryo and endometrium. Endometrial receptivity analysis (ERA) may identify the window of implantation and guide the timing of embryo transfer to improve the pregnancy outcomes. However, there is no randomized controlled trial on the clinical effectiveness of ERA in women with RIF.\n\nThis is a multicenter double-blind randomized controlled trial. All participants will have an endometrial biopsy for ERA in a standard hormonal treatment cycle. They will then be randomly assigned in the central laboratory into the intervention or control group in a 1:1 ratio. At the transfer cycle, participants in the intervention group will have frozen embryo transfer timed according to the results of ERA while those in the control group will have the transfer according to the standard timing. The primary outcome is the ongoing pregnancy rate at 10-12 weeks at their first frozen embryo transfer.",[27,106],[212,213,129,69,214,215],"Endometrial receptivity analysis","ERA","frozen embryo transfer","FET","2025-03-24",{"date":218,"type":38},"2025-03-26",{"date":220,"type":38},"2025-02-15",{"date":222,"type":21},"2028-06-30",{"name":224,"class":45},"The University of Hong Kong",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":180,"enrollmentInfo":232,"targetDuration":4,"studyType":22,"phases":233,"briefSummary":234,"conditions":235,"keywords":4,"overallStatus":162,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":122},"100354888","preimplantation-genetic-testing-for-aneuploidies-in-patients-with-recurrent-implantation-failure-100354888","NCT03900780","Preimplantation Genetic Testing for Aneuploidies in Patients With Recurrent Implantation Failure","Preimplantion Genetic Testing for Aneuploidies (PGT-A) in Patients With Recurrent Implantation Failure: a Pilot RCT","Inclusion Criteria:\n\n* Women with recurrent implantation failure (previous transfer of least 4 good quality embryos in at least 3 fresh or frozen cycles)\n* BMI \\\u003C 35\n* Normal hysteroscopy\n\nExclusion Criteria:\n\n* thin endometrium in previous cycles (\\\u003C6mm), endometriosis ASRM score III-IV, premature ovarian failure (POF, Bologna criteria), abnormal karyotype, donor oocytes or embryos, PGT-M",{"count":94,"type":21},[24],"Assessing whether Preimplantation Genetic Testing for Aneuploidy (PGT-A) can increase the ongoing pregnancy rate per transferred embryo and can decrease the time to pregnancy and miscarriage rate in patients with Recurrent Implantation Failure (RIF)",[27],"2025-02-25",{"date":238,"type":38},"2025-02-26",{"date":240,"type":38},"2019-05-01",{"date":242,"type":21},"2026-12-31",{"name":244,"class":45},"Universitaire Ziekenhuizen KU Leuven"]